What will the new "Ryplazim partnership" include?I am not that clear on what the new "Ryplazim partnership" would include. I have 3 possibilities in mind, 1) it only includes the rights to what will be included under the current expected FDA approval in H1 - Ryplazim™ for the only current indication for treatment of PLGD, or 2) It will also include all rights to all future developments and indications to be treated by Ryplazim for any indication yet to be developed, or 3) this is but a short form terminology that really includes all future protein therapeutics for all plasma derived therapeutics? Until now my understanding has been 1) but I have never really been clear on this. If in fact it is 1), then there will not be very big dollars on the partnership announcement. Anyone have any clarity on this?